{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:01:41Z","timestamp":1774551701272,"version":"3.50.1"},"reference-count":26,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2021,3,30]]},"DOI":"10.1536\/ihj.20-508","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T22:08:28Z","timestamp":1615932508000},"page":"246-255","source":"Crossref","is-referenced-by-count":4,"title":["Reduced-Dose Prasugrel versus Clopidogrel for Patients Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1536","volume":"62","author":[{"given":"Cheng-Han","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University"},{"name":"Department of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu-Shiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University"},{"name":"Institute of Clinical Medicine, College of Medicine, National Cheng Kung University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Hsing","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Hsiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, College of Medicine, National Cheng Kung University"},{"name":"Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University"},{"name":"Department of Public Health, College of Medicine, National Cheng Kung University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Heng","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Valgimigli M, Bueno H, Byrne RA, <i>et al<\/i>. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213-60.","DOI":"10.1093\/eurheartj\/ehx419"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Levine GN, Bates ER, Bittl JA, <i>et al<\/i>. 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68: 1082-115.","DOI":"10.1016\/j.jacc.2016.03.513"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jeong YH.  &quot;East asian paradox&quot;: challenge for the current antiplatelet strategy of &quot;one-guideline-fits-all races&quot; in acute coronary syndrome. Curr Cardiol Rep 2014; 16: 485.","DOI":"10.1007\/s11886-014-0485-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wiviott SD, Braunwald E, McCabe CH, <i>et al<\/i>. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.","DOI":"10.1056\/NEJMoa0706482"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Isshiki T, Kimura T, Ogawa H, <i>et al<\/i>. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J 2014; 78: 2926-34.","DOI":"10.1253\/circj.CJ-14-0266"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Saito S, Isshiki T, Kimura T, <i>et al<\/i>. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014; 78: 1684-92.","DOI":"10.1253\/circj.CJ-13-1482"},{"key":"7","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","year":"2000","unstructured":"7. Stroup DF, Berlin JA, Morton SC, <i>et al<\/i>. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Liberati A, Altman DG, Tetzlaff J, <i>et al<\/i>. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.","DOI":"10.1136\/bmj.b2700"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kim SY, Park JE, Lee YJ, <i>et al<\/i>. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013; 66: 408-14.","DOI":"10.1016\/j.jclinepi.2012.09.016"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Koyabu Y, Abe S, Sakuma M, <i>et al<\/i>. Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Intern Med 2019; 58: 2315-22.","DOI":"10.2169\/internalmedicine.2262-18"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yasuda S, Honda S, Takegami M, <i>et al<\/i>. Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction - Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR). Circ J 2019; 83: 1633-43.","DOI":"10.1253\/circj.CJ-19-0145"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Akita K, Inohara T, Yamaji K, <i>et al<\/i>. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan. Eur Heart J Cardiovasc Pharmacother 2020; 6: 231-8.","DOI":"10.1093\/ehjcvp\/pvz056"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shoji S, Sawano M, Sandhu AT, <i>et al<\/i>. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. JAMA Netw Open 2020; 3: e202004.","DOI":"10.1001\/jamanetworkopen.2020.2004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Savonitto S, Ferri LA, Piatti L, <i>et al<\/i>. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation 2018; 137: 2435-45.","DOI":"10.1161\/CIRCULATIONAHA.117.032180"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Redfors B, G\u00e9n\u00e9reux P, Witzenbichler B, <i>et al<\/i>. Bleeding Severity After Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2018; 11: e005542.","DOI":"10.1161\/CIRCINTERVENTIONS.117.005542"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Costa F, Van Klaveren D, Feres F, <i>et al<\/i>. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol 2019; 73: 741-54.","DOI":"10.1016\/j.jacc.2018.11.048"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Levine GN, Jeong YH, Goto S, <i>et al<\/i>. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11: 597-606.","DOI":"10.1038\/nrcardio.2014.104"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kang J, Park KW, Palmerini T, <i>et al<\/i>. Racial Differences in Ischaemia\/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thromb Haemost 2019; 119: 149-62.","DOI":"10.1055\/s-0038-1676545"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yokoi H, Kimura T, Isshiki T, Ogawa H, Ikeda Y. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thromb Res 2012; 129: 623-8.","DOI":"10.1016\/j.thromres.2011.11.023"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kimura K, Kimura T, Ishihara M, <i>et al<\/i>. JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circ J 2019; 83: 1085-196.","DOI":"10.1253\/circj.CJ-19-0133"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc 2006; 81: 641-52.","DOI":"10.4065\/81.5.641"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Buonamici P, Marcucci R, Migliorini A, <i>et al<\/i>. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-7.","DOI":"10.1016\/j.jacc.2007.01.094"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Brar SS, ten Berg J, Marcucci R, <i>et al<\/i>. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-54.","DOI":"10.1016\/j.jacc.2011.06.059"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Montalescot G, Bolognese L, Dudek D, <i>et al<\/i>. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010.","DOI":"10.1056\/NEJMoa1308075"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sch\u00fcpke S, Neumann FJ, Menichelli M, <i>et al<\/i>. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med 2019; 381: 1524-34.","DOI":"10.1056\/NEJMoa1908973"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Collet JP, Thiele H, Barbato E, <i>et al<\/i>. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020. (in press).","DOI":"10.1093\/eurheartj\/ehaa909"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/2\/62_20-508\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:58:50Z","timestamp":1617422330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/2\/62_20-508\/_article"}},"subtitle":["A Meta-Analysis of Randomized and Observational Studies"],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-508","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}